Robert B Kargbo

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 145

Top Venues

ACS medicinal chemistry letters

Journal of xenobiotics

Journal of the American Chemical Society

ACS omega

Usona Institute

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Usona Institute

United States

Medicinal Chemist :: Medicinal Chemistry

Publications

Robert B Kargbo
Expanding TPD Horizons: Innovative Strategies Targeting BCL6 and SMARCA2. ACS medicinal chemistry letters 15 (5) (2024)
Robert B Kargbo
Redefining Neurodegenerative Treatment: Synergy of KEAP1, PROTACs, and Inflammatory Modulators. ACS medicinal chemistry letters 15 (2) (2024)
Robert B Kargbo
Advancing Neurological Therapies: Integrating Novel Compounds and Clinical Trials for Enhanced Cognitive and Neuronal Health. ACS medicinal chemistry letters 15 (7) (2024)
Robert B Kargbo
AI in Pharma: Transforming Drug Discovery and Strategic Management with MYC-Modulating Compounds and BET Protein Inhibitors. ACS medicinal chemistry letters 15 (3) (2024)
Robert B Kargbo
Lysosomal Degradation of Extracellular Targets: Innovations and Implications. ACS medicinal chemistry letters 15 (6) (2024)
Robert B Kargbo
Innovations in Pharmacology: Enhancing Bioavailability and Efficacy through Novel Compositions. ACS medicinal chemistry letters 15 (3) (2024)
Robert B Kargbo
Advancements in Protein Degradation for Cancer Therapy. ACS medicinal chemistry letters 15 (7) (2024)
Robert B Kargbo
Exploring the Therapeutic Potential of Entheogens in Postoperative Cognitive Decline and Psychological Resilience. ACS medicinal chemistry letters 15 (9) (2024)
Robert B Kargbo
Current Trends in Psychedelic Science: Integrating Modified Lysergic Acid Derivatives and Psilocybin in Modern Medicine. ACS medicinal chemistry letters 15 (9) (2024)
Robert B Kargbo
Innovative Ketamine Formulations: Enhancing Therapeutic Efficacy and Safety. ACS medicinal chemistry letters 15 (8) (2024)
Robert B Kargbo
Innovative Drug Discovery: Targeting Cancer, Neurological Disorders, and Obesity. ACS medicinal chemistry letters 15 (9) (2024)
Robert B Kargbo
Advancements in Psychoactive Alkaloid Delivery, Neuroenhancement, and Psychedelic Therapies: Exploring the Frontiers of Modern Pharmacology. ACS medicinal chemistry letters 15 (6) (2024)
Robert B Kargbo
Innovative Therapeutic Approaches Targeting K-Ras: Analysis of Macrocyclic Compounds, Peptidomimetics, and Pyridopyrimidine Inhibitors. ACS medicinal chemistry letters 15 (8) (2024)
Robert B Kargbo
Toward Precision Oncology: The Role of TPD in Targeting CDK2 and Beyond. ACS medicinal chemistry letters 15 (7) (2024)
Robert B Kargbo
Advancements in Predictive Medicine: NLRP3 Inflammasome Inhibitors and AI-Driven Predictive Health Analytics. ACS medicinal chemistry letters 15 (3) (2024)
Robert B Kargbo
The New Frontier in Neurotherapeutics: From Brain Stimulation to Novel Psychotropics. ACS medicinal chemistry letters 15 (7) (2024)
Robert B Kargbo
Innovative Therapeutic Approaches Targeting K-Ras: Analysis of Macrocyclic Compounds, Peptidomimetics, and Pyridopyrimidine Inhibitors. ACS medicinal chemistry letters 15 (8) (2024)
Robert B Kargbo
Integrating Neuroprotective and Anti-inflammatory Strategies in the Development of PI3K Inhibitors for Enhanced Cancer Therapy. ACS medicinal chemistry letters 15 (8) (2024)
Robert B Kargbo
Advances in Targeted Therapies for Inflammatory Diseases and Cancer: Exploring Cellular Mechanisms and Therapeutic Strategies. ACS medicinal chemistry letters 15 (6) (2024)
Robert B Kargbo
Pioneering Methods in Brain Optimization and Mental Health Treatment. ACS medicinal chemistry letters 15 (3) (2024)
Robert B Kargbo
Neuropharmacological Advances: Harnessing 5-HT2A Receptor Modulators and Psychoplastogens. ACS medicinal chemistry letters 15 (2) (2024)
Robert B Kargbo
Innovations in Pharmacology: Enhancing Bioavailability and Efficacy through Novel Compositions. ACS medicinal chemistry letters 15 (3) (2024)
Robert B Kargbo
Transforming Therapeutic Approaches with PROTAC Technology: New Targets and Potentials. ACS medicinal chemistry letters 15 (5) (2024)
Robert B Kargbo
Innovations in Precision Oncology: Biomarker-Driven Approaches for Enhanced Cancer Therapy. ACS medicinal chemistry letters 15 (2) (2024)
Robert B Kargbo
Treatment of Metabolic Disorders Using Novel DGAT2 Inhibitors: Pyrazolopyridine and Triazolopyridine Derivatives. ACS medicinal chemistry letters 15 (8) (2024)
Robert B Kargbo
Novel Approaches for Upregulation of Tumor Suppressor Proteins: Pioneering Strategies and Integrative Potentials. ACS medicinal chemistry letters 15 (6) (2024)
Robert B Kargbo
The New Frontier in Neurotherapeutics: From Brain Stimulation to Novel Psychotropics. ACS medicinal chemistry letters 15 (7) (2024)
Robert B Kargbo
Innovations in Precision Oncology: Biomarker-Driven Approaches for Enhanced Cancer Therapy. ACS medicinal chemistry letters 15 (2) (2024)
Robert B Kargbo
New Directions in Antibacterial, Anticancer, and Gene Editing Therapies. ACS medicinal chemistry letters 15 (9) (2024)
Robert B Kargbo
Innovative Therapeutic Strategies in TYK2-Targeted Treatments: From Cancer to Autoimmune Disorders. ACS medicinal chemistry letters 15 (2) (2024)
Robert B Kargbo
Transforming Therapeutic Approaches with PROTAC Technology: New Targets and Potentials. ACS medicinal chemistry letters 15 (5) (2024)
Robert B Kargbo
Advancements in Predictive Medicine: NLRP3 Inflammasome Inhibitors and AI-Driven Predictive Health Analytics. ACS medicinal chemistry letters 15 (3) (2024)
Robert B Kargbo
Integrating Neuroprotective and Anti-inflammatory Strategies in the Development of PI3K Inhibitors for Enhanced Cancer Therapy. ACS medicinal chemistry letters 15 (8) (2024)
Robert B Kargbo
AI in Pharma: Transforming Drug Discovery and Strategic Management with MYC-Modulating Compounds and BET Protein Inhibitors. ACS medicinal chemistry letters 15 (3) (2024)
Robert B Kargbo
Emerging Techniques in Cancer Therapy: Precision Targeting for Improved Outcomes. ACS medicinal chemistry letters 15 (9) (2024)
Robert B Kargbo
Novel Approaches for Upregulation of Tumor Suppressor Proteins: Pioneering Strategies and Integrative Potentials. ACS medicinal chemistry letters 15 (6) (2024)
Robert B Kargbo
Advances in Targeted Therapies for Inflammatory Diseases and Cancer: Exploring Cellular Mechanisms and Therapeutic Strategies. ACS medicinal chemistry letters 15 (6) (2024)
Robert B Kargbo
Expanding TPD Horizons: Innovative Strategies Targeting BCL6 and SMARCA2. ACS medicinal chemistry letters 15 (5) (2024)
Robert B Kargbo
Pioneering Methods in Brain Optimization and Mental Health Treatment. ACS medicinal chemistry letters 15 (3) (2024)
Robert B Kargbo
Advancements in Targeted Therapeutics: Integrating Metabolic Modulation, Immune Engineering, and Biologic Formulation Technologies. ACS medicinal chemistry letters 15 (9) (2024)
Robert B Kargbo
Advancing Neurological Therapies: Integrating Novel Compounds and Clinical Trials for Enhanced Cognitive and Neuronal Health. ACS medicinal chemistry letters 15 (7) (2024)
Robert B Kargbo
Neuropharmacological Advances: Harnessing 5-HT2A Receptor Modulators and Psychoplastogens. ACS medicinal chemistry letters 15 (2) (2024)
Robert B Kargbo
Advancements in Protein Degradation for Cancer Therapy. ACS medicinal chemistry letters 15 (7) (2024)
Robert B Kargbo
Redefining Neurodegenerative Treatment: Synergy of KEAP1, PROTACs, and Inflammatory Modulators. ACS medicinal chemistry letters 15 (2) (2024)
Robert B Kargbo
Treatment of Metabolic Disorders Using Novel DGAT2 Inhibitors: Pyrazolopyridine and Triazolopyridine Derivatives. ACS medicinal chemistry letters 15 (8) (2024)
Robert B Kargbo
Advancements in Psychoactive Alkaloid Delivery, Neuroenhancement, and Psychedelic Therapies: Exploring the Frontiers of Modern Pharmacology. ACS medicinal chemistry letters 15 (6) (2024)
Robert B Kargbo
Innovative Ketamine Formulations: Enhancing Therapeutic Efficacy and Safety. ACS medicinal chemistry letters 15 (8) (2024)
Robert B Kargbo
Innovative Therapeutic Strategies in TYK2-Targeted Treatments: From Cancer to Autoimmune Disorders. ACS medicinal chemistry letters 15 (2) (2024)
Robert B Kargbo
Lysosomal Degradation of Extracellular Targets: Innovations and Implications. ACS medicinal chemistry letters 15 (6) (2024)
Robert B Kargbo
Toward Precision Oncology: The Role of TPD in Targeting CDK2 and Beyond. ACS medicinal chemistry letters 15 (7) (2024)
Robert B Kargbo
Expanding the Chemical Space: New Approach to Cell-Permeable Drugs. ACS medicinal chemistry letters 14 (10) (2023)
Robert B Kargbo
KRAS-Degrading Compounds: A Novel Approach to Treat Cancer by Targeting Both Wild-Type and Mutated KRAS Forms. ACS medicinal chemistry letters 14 (11) (2023)
Robert B Kargbo
Small-Molecule Heterocyclic Compounds: Gq-Biased Agonists for the 5-HT2A Receptor in Neuropsychiatric Treatment. ACS medicinal chemistry letters 14 (11) (2023)
Robert B Kargbo
Microbiome: The Next Frontier in Psychedelic Renaissance. Journal of xenobiotics 13 (3) (2023)
Robert B Kargbo
Targeted Combination Therapies: A New Frontier in the Treatment of TP53 and KRAS Mutation-Associated Cancers. ACS medicinal chemistry letters 15 (1) (2023)
Robert B Kargbo
Microbiome-Gut-Brain Axis Modulation: New Approaches in Treatment of Parkinson's Disease and Amyotrophic Lateral Sclerosis. ACS medicinal chemistry letters 14 (7) (2023)
Robert B Kargbo
Exploring Next-Generation Therapeutics: Morphic Mixtures and Specified Salts for the Treatment of Mental Disorders and CNS Modulation. ACS medicinal chemistry letters 14 (9) (2023)
Robert B Kargbo
Discovery of Potent Deuterated Compounds as Potential KRAS G12D Inhibitors in Cancer Therapy. ACS medicinal chemistry letters 14 (4) (2023)
Robert B Kargbo
Psychedelic-Assisted Neuroplasticity for the Treatment of Mental Health Disorders. ACS medicinal chemistry letters 14 (2) (2023)
Robert B Kargbo
Orally Active Forms of DMT, 5-MeO-DMT, and Long-Acting MDMA for the Treatment of Neuropsychiatric Disorders. ACS medicinal chemistry letters 14 (4) (2023)
Robert B Kargbo
PROTAC: Harnessing Targeted Chimeras for Selective BCL-2 Degradation in Cancer Treatment. ACS medicinal chemistry letters 14 (5) (2023)
Robert B Kargbo
Psychoplastogens: A Novel Therapeutic Approach for Neurological Diseases and Disorders. ACS medicinal chemistry letters 14 (9) (2023)
Robert B Kargbo
Redefining Cancer Therapy: Toward BCL-XL/BCL-2 Dual Inhibitors with Diminished Platelet Toxicity. ACS medicinal chemistry letters 14 (9) (2023)
Robert B Kargbo
Effective Combination Therapies for the Treatment of HER2 Cancer. ACS medicinal chemistry letters 14 (3) (2023)
Robert B Kargbo
PROTAC: Harnessing Targeted Chimeras for Selective BCL-2 Degradation in Cancer Treatment. ACS medicinal chemistry letters 14 (5) (2023)
Robert B Kargbo
Discovery of Selective Aldehyde Dehydrogenase Inhibitors for the Treatment of Cancer. ACS medicinal chemistry letters 14 (2) (2023)
Robert B Kargbo
Unveiling New KRAS G12D Inhibitors: A Promising Approach for Pancreatic Cancer Therapy. ACS medicinal chemistry letters 14 (7) (2023)
Robert B Kargbo
Targeted Degradation of CDK4/6: An Innovative Approach to Overcoming Cancer Drug Resistance. ACS medicinal chemistry letters 14 (9) (2023)
Robert B Kargbo
Tryptamines and Mental Health: Activating the 5-HT Receptor for Therapeutic Potential. ACS medicinal chemistry letters 14 (10) (2023)
Robert B Kargbo
PARP7 Inhibition: A Promising Pathway to Advancements in Cancer Therapy. ACS medicinal chemistry letters 14 (9) (2023)
Robert B Kargbo
Targeting KRAS G12D Mutations: Discovery of Small Molecule Inhibitors for the Potential Treatment of Intractable Cancers. ACS medicinal chemistry letters 14 (8) (2023)
Robert B Kargbo
Development and Utilization of Novel Transglutaminase 2 Inhibitors for Potential Treatment of Autoimmune Disease and Gastrointestinal Disorder. ACS medicinal chemistry letters 14 (11) (2023)
Robert B Kargbo
Discovery of Selective Aldehyde Dehydrogenase Inhibitors for the Treatment of Cancer. ACS medicinal chemistry letters 14 (2) (2023)
Robert B Kargbo
Pioneering Changes in Psychiatry: Biomarkers, Psychedelics, and AI. ACS medicinal chemistry letters 14 (9) (2023)
Robert B Kargbo
Targeted Degradation of KRAS G12D as Potential Therapy in Cancer. ACS medicinal chemistry letters 14 (5) (2023)
Robert B Kargbo
Subhallucinogenic Concentrations of Substituted Phenethylamines as a Novel Therapeutic Approach for Inflammatory and Neurological Disorders. ACS medicinal chemistry letters 14 (7) (2023)
Robert B Kargbo
Psychedelic-Assisted Neuroplasticity for the Treatment of Mental Health Disorders. ACS medicinal chemistry letters 14 (2) (2023)
Robert B Kargbo
PROTAC Targeted Degradation of IRAK-4 as Potential Treatment in Cancer. ACS medicinal chemistry letters 14 (5) (2023)
Robert B Kargbo
Discovery of Selective and Potent KRAS G12D Inhibitors as Potential Therapy in Cancer. ACS medicinal chemistry letters 14 (6) (2023)
Robert B Kargbo
Cyclin-Dependent Kinase Degradation via E3 Ligase Binding for Potential Disease Modulation in Cancer Treatment. ACS medicinal chemistry letters 14 (8) (2023)
Robert B Kargbo
Microbiome-Gut-Brain Axis Modulation: New Approaches in Treatment of Neuropsychological and Gastrointestinal Functional Disorders. ACS medicinal chemistry letters 14 (6) (2023)
Robert B Kargbo
PROTAC Targeted Degradation of IRAK-4 as Potential Treatment in Cancer. ACS medicinal chemistry letters 14 (5) (2023)
Robert B Kargbo
Perceptual Modifying Compounds and Their Potential Therapeutic Applications in Neuropsychiatric Disorders. ACS medicinal chemistry letters 15 (1) (2023)
Robert B Kargbo
Unraveling Psychedelic Responses: Targeted Protein Degradation and Genetic Diversity. ACS medicinal chemistry letters 14 (8) (2023)
Robert B Kargbo
New Horizons in Cancer Treatment: A Closer Look at Novel PI3Kα Inhibitors. ACS medicinal chemistry letters 14 (9) (2023)
Robert B Kargbo
Targeted Degradation of KRAS G12D as Potential Therapy in Cancer. ACS medicinal chemistry letters 14 (5) (2023)
Robert B Kargbo
Neurosteroids and Postpartum Depression: The Mechanism, Efficacy, and Approval of Brexanolone and Zurzuvae. ACS medicinal chemistry letters 14 (10) (2023)
Robert B Kargbo
Targeting the "Undruggable" Driver Protein, KRAS G12D , as Potential Therapy in Prostate Cancer. ACS medicinal chemistry letters 14 (4) (2023)
Robert B Kargbo
The Synergistic Effects of 5-HT2A and TRP Agonism/Antagonism in Reducing Inflammation for Enhanced Mental and Physical Health. ACS medicinal chemistry letters 14 (8) (2023)
Robert B Kargbo
Perceptual Modifying Compounds and Their Potential Therapeutic Applications in Neuropsychiatric Disorders. ACS medicinal chemistry letters 15 (1) (2023)
Robert B Kargbo
Targeted Combination Therapies: A New Frontier in the Treatment of TP53 and KRAS Mutation-Associated Cancers. ACS medicinal chemistry letters 15 (1) (2023)
Robert B Kargbo
Potent and Selective BCL-XL Inhibitors and PROTAC Compounds as Potential Cancer Treatment and Immunotherapy. ACS medicinal chemistry letters 14 (6) (2023)
Robert B Kargbo
Application of Rapidly Accelerating Fibrosarcoma Protein Degraders in Drug Discovery. ACS medicinal chemistry letters 13 (6) (2022)
Robert B Kargbo
Therapeutic and Effective CURE-PRO Molecules for E3 Ligase-Mediated Targeted Protein Degradation. ACS medicinal chemistry letters 13 (8) (2022)
Robert B Kargbo
Restoration of Motor Function Post-Neurological Injury Using Serotonergic Agonist. ACS medicinal chemistry letters 13 (9) (2022)
Robert B Kargbo
MDMA and Their Analogs as Therapeutics for Mental Disorder and Response Predictor. ACS medicinal chemistry letters 13 (10) (2022)
Robert B Kargbo
Application of Degradation of Cyclic-AMP Response Element Binding Protein for the Potential Treatment of Cancer. ACS medicinal chemistry letters 13 (8) (2022)
Robert B Kargbo
Potent PROTACs Targeting EGFR Mutants in Drug Discovery. ACS medicinal chemistry letters 13 (12) (2022)
Robert B Kargbo
Application of Deuterated N , N -Dimethyltryptamine in the Potential Treatment of Psychiatric and Neurological Disorders. ACS medicinal chemistry letters 13 (9) (2022)
Robert B Kargbo
SARS-CoV-2: Novel Therapeutic Approaches for Diagnosis and Treatment. ACS medicinal chemistry letters 13 (7) (2022)

Robert B Kargbo.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Robert B Kargbo